<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.2.1.5134
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the U.S. Securities and Exchange Commission on March 17, 2023</div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="font-size: 14pt;">UNITED STATES</font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">ANGION BIOMEDICA CORP.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7ea16a9d770342009c8a34f8947eb682" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">11-3430072</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-weight: bold;">7-57 Wells Avenue, Newton, Massachusetts<font style="font-weight: bold;"> </font> 02459</font></div>
    <div style="text-align: center; font-weight: bold;">(Address of principal executive offices, including zip code)</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-weight: bold;">Angion Biomedica Corp.&#160; 2021 Incentive Award Plan</div>
    <div style="text-align: center; font-weight: bold;">Angion Biomedica Corp.&#160; 2021 Employee Stock Purchase Plan</div>
    <div style="text-align: center; font-weight: bold;">(Full titles of the plans)</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-weight: bold;">Jay R. Venkatesan, M.D.</div>
    <div style="text-align: center; font-weight: bold;">Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">Angion Biomedica Corp.</div>
    <div style="text-align: center; font-weight: bold;">7-57 Wells Avenue, Newton, Massachusetts</div>
    <div style="text-align: center; font-weight: bold;">02459</div>
    <div style="text-align: center; font-weight: bold;">(415) 655-4899</div>
    <div style="text-align: center; font-weight: bold;">(Name, address and telephone number, including area code, of agent for service)</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-style: italic;">Copies to:</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb664b51968924919ae033a5c6af90517" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Jennifer J. Rhodes</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">Kenneth Guernsey</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">General Counsel</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">Brett White</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Angion Biomedica Corp.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">Cooley LLP</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">7-57 Wells Avenue, Newton, Massachusetts</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">3 Embarcadero Center,</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">&#160;02459</div>
            <div style="text-align: center; font-weight: bold;">(415) 655-4899</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">20<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
              <div style="text-align: center; font-weight: bold;">San Francisco, CA 94111</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div>
              <div style="text-align: center; font-weight: bold;">(415) 693-2000</div>
            </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 27.35pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
      accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2629174a23fa44178456ae82aaeeb109" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: justify;">Large accelerated filer<br>
            </div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: top;">&#9744;</td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: justify;">Accelerated filer<br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#9744;</td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: justify;">Non-accelerated filer</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: top;">&#9746;</td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: justify;">Smaller reporting company</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#9746;</td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: justify;">Emerging growth company</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#9746;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 27pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
      provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744; </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">EXPLANATORY NOTE</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">Pursuant to General Instruction E of Form S-8, Angion Biomedica Corp. (the &#8220;Registrant&#8221;) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the
      &#8220;Commission&#8221;) for the purpose of registering (i) 1,505,662 additional shares of its common stock, par value $0.01 per share under the Angion Biomedica Corp.&#160; 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;), pursuant to the provisions of the 2021 Plan
      providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2021 Plan on January 1, 2022, and (ii) 301,132 additional shares of its common stock under the Angion Biomedica Corp.&#160; 2021
      Employee Stock Purchase Plan (the &#8220;2021 ESPP,&#8221; and together with the 2021 Plan, the &#8220;Plans&#8221;), pursuant to the provisions of the 2021 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance
      under the 2021 ESPP on December 31, 2022. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">This Registration Statement relates to securities of the same class as those for which earlier Registration Statements on Form S-8 were filed with the Commission on February 9, 2021 (File No.
      333-252906) and May 16, 2022 (File No. 333-264995) (collectively, the &#8220;Prior Registration Statements&#8221;). Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of
      Common Stock issuable under the 2021 Plan and the 2021 ESPP, are incorporated by reference into this Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: center; text-indent: 24.5pt; font-weight: bold;">Part II</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="font-weight: bold;">Item 3. Incorporation of Documents by Reference.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">(a)</font> The Registrant&#8217;s Annual Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148523000011/angn-20221231.htm">Form 10-K</a> (File No.
      001-39990) for the fiscal year ended December 31, 2022, filed with the SEC on March 17, 2023.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">(b)</font> The Registrant&#8217;s Current Reports on Form 8-K (File No. 001-39990) filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_8k.htm">January 17, 2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1601485/000160148523000004/angn-20230309.htm">March 14, 2023</a>;</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">(c)</font> The description of the Registrant&#8217;s common stock which is contained in a Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921010887/a20-5764_88a12b.htm">Form 8-A</a> filed on February 2, 2021 (File No. 001-39990) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as updated by <a href="https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angion-descriptionofsecuri.htm">Exhibit 4.5</a> to the Registrant's Annual Report on Form 10-K filed with the SEC on March 30, 2022, including any amendments or reports filed
      for the purpose of updating such description.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">(d)</font> All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished
      under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which
      indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such
      reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement
      contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or
      superseded, to constitute a part of this Registration Statement.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
  </div>
  <div>
    <div><br>
    </div>
    <div style="margin-left: 0.5pt;"><font style="font-weight: bold;">ITEM 8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">EXHIBITS</font></div>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf9db895044584116b9a388368626d329" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td colspan="7" rowspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div><font style="font-weight: bold;">Incorporated by Reference</font> </div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Exhibit Number</div>
            </div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Exhibit Description</div>
            </div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 6%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Form</div>
            </div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 7.66%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">File No.</div>
            </div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Exhibit</div>
            </div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10.85%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Filing Date</div>
            </div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-1.htm">4.1</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: justify;">Amended and Restated Certificate of Incorporation of Angion Biomedica Corp.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>8-K</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">
            <div style="text-align: center;">001-39990</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">
            <div>3.1</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">
            <div>February 9, 2021</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-2.htm">4.2</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Bylaws of Angion Biomedica Corp.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>8-K</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">
            <div style="text-align: center;">001-39990</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">
            <div>3.2</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">
            <div>February 9, 2021</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="ny20006674x8_ex5-1.htm">5.1*</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Opinion of Cooley LLP.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="ny20006674x8_ex23-1.htm">23.1*</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Consent of Moss Adams LLP, independent registered public accounting firm.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="ny20006674x8_ex5-1.htm">23.3*</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Consent of Cooley LLP (included in Exhibit 5.1 hereto).</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="#POWEROFATTORNEY">24.1*</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Power of Attorney (included on the signature page hereto).</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6a.htm">99.1</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Angion Biomedica Corp.&#160; 2021 Incentive Award Plan.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>10-K</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">
            <div style="text-align: center;">001-39990</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">
            <div>10.6(a)</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">
            <div>March 30, 2022</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div>99.2</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Form of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>10-K</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">
            <div style="text-align: center;">001-39990</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6b.htm">10.6(b)</a>, <a href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6c.htm">10.6(c)</a>, <a href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6d.htm">10.6(d)</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">
            <div>March 30, 2022</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_7.htm">99.3</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Angion Biomedica Corp. 2021 Employee Stock Purchase Plan.</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>10-K</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">
            <div style="text-align: center;">001-39990</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">
            <div>10.7</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">
            <div>March 30, 2022</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 49%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="ny20006674x8_ex107.htm">107*</a></div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div>Filing Fee Table</div>
          </td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 7.66%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 11%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 10.85%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>* Filed herewith.</div>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
      caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Park City, State of Utah, on this 17th day of March, 2023.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z55af55c96cdf4867aaaaea89adc3b8fb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.89%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.11%; vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">ANGION BIOMEDICA CORP. </div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.89%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="width: 50.11%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.89%; vertical-align: top;">&#160;</td>
          <td style="width: 3.21%; vertical-align: top;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 46.9%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">/s/ <font style="font-style: italic;">Jay Venkatesan</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.89%; vertical-align: top;">&#160;</td>
          <td style="width: 3.21%; vertical-align: top;">&#160;</td>
          <td style="width: 46.9%; vertical-align: top;">
            <div>Jay Venkatesan, M.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.89%; vertical-align: top;">&#160;</td>
          <td style="width: 3.21%; vertical-align: top;">&#160;</td>
          <td style="width: 46.9%; vertical-align: top;">
            <div>Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
    <div><br>
    </div>
    <div style="text-align: justify;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jay R. Venkatesan, M.D. and Jennifer J. Rhodes, and each one of them, as his or her true and lawful
      attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration
      Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and
      perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
      or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z33db3152a1a74c34a1e694c91b57fabe" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center; font-weight: bold;">Signature</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center; font-weight: bold;">Title</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center; font-weight: bold;">Date</div>
            </div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 39%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Jay R. Venkatesan, M.D.</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Chief Executive Officer and Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Jay R. Venkatesan, M.D.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>&#160;<font style="font-style: italic;">(Principal Executive Officer)</font></div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div>
              <div>/s/ Gregory S. Curhan</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Chief Financial Officer and Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top; text-align: center;">March 17, 2023</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Gregory S. Curhan</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>&#160;<font style="font-style: italic;">(Principal Financial and Accounting Officer)</font></div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;"><br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Itzhak D. Goldberg, M.D.</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Itzhak D. Goldberg, M.D.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Victor F. Ganzi</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Victor F. Ganzi</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Allen R. Nissenson, M.D.</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Allen R. Nissenson, M.D.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Gilbert S. Omenn, M.D., Ph.D.</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Gilbert S. Omenn, M.D., Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center;">/s/ Karen J. Wilson</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">
            <div>Director</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">
            <div style="text-align: center;">March 17, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center;">Karen J. Wilson</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 39%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ny20006674x8_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 57227}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-270676", "film-number": "23743773"}, "business-address": {"street1": "7-57 WELLS AVENUE", "city": "NEWTON", "state": "MA", "zip": "02459", "phone": "(415) 655-4899"}, "mail-address": {"street1": "7-57 WELLS AVENUE", "city": "NEWTON", "state": "MA", "zip": "02459"}}
As filed with the U.S. Securities and Exchange Commission on March 17, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
11-3430072
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
7-57 Wells Avenue, Newton, Massachusetts
02459
(Address of principal executive offices, including zip code)
Angion Biomedica Corp.  2021 Incentive Award Plan
Angion Biomedica Corp.  2021 Employee Stock Purchase Plan
(Full titles of the plans)
Jay R. Venkatesan, M.D.
Chief Executive Officer
Angion Biomedica Corp.
7-57 Wells Avenue, Newton, Massachusetts
02459
(415) 655-4899
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Jennifer J. Rhodes
Kenneth Guernsey
General Counsel
Brett White
Angion Biomedica Corp.
Cooley LLP
7-57 Wells Avenue, Newton, Massachusetts
3 Embarcadero Center,
02459
(415) 655-4899
20
th
Floor
San Francisco, CA 94111
(415) 693-2000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large
      accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
      provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Pursuant to General Instruction E of Form S-8, Angion Biomedica Corp. (the "Registrant") is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the
      "Commission") for the purpose of registering (i) 1,505,662 additional shares of its common stock, par value $0.01 per share under the Angion Biomedica Corp.  2021 Incentive Award Plan (the "2021 Plan"), pursuant to the provisions of the 2021 Plan
      providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2021 Plan on January 1, 2022, and (ii) 301,132 additional shares of its common stock under the Angion Biomedica Corp.  2021
      Employee Stock Purchase Plan (the "2021 ESPP," and together with the 2021 Plan, the "Plans"), pursuant to the provisions of the 2021 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance
      under the 2021 ESPP on December 31, 2022. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
This Registration Statement relates to securities of the same class as those for which earlier Registration Statements on Form S-8 were filed with the Commission on February 9, 2021 (File No.
      333-252906) and May 16, 2022 (File No. 333-264995) (collectively, the "Prior Registration Statements"). Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of
      Common Stock issuable under the 2021 Plan and the 2021 ESPP, are incorporated by reference into this Registration Statement.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a)
The Registrant's Annual Report on
Form 10-K
(File No.
      001-39990) for the fiscal year ended December 31, 2022, filed with the SEC on March 17, 2023.
(b)
The Registrant's Current Reports on Form 8-K (File No. 001-39990) filed with the SEC on
January 17, 2023
and
March 14, 2023
;
(c)
The description of the Registrant's common stock which is contained in a Registration Statement on
Form 8-A
filed on February 2, 2021 (File No. 001-39990) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as updated by
Exhibit 4.5
to the Registrant's Annual Report on Form 10-K filed with the SEC on March 30, 2022, including any amendments or reports filed
      for the purpose of updating such description.
(d)
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished
      under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which
      indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such
      reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement
      contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or
      superseded, to constitute a part of this Registration Statement.
ITEM 8.
EXHIBITS
Incorporated by Reference
Exhibit Number
Exhibit Description
Form
File No.
Exhibit
Filing Date
4.1
Amended and Restated Certificate of Incorporation of Angion Biomedica Corp.
8-K
001-39990
3.1
February 9, 2021
4.2
Bylaws of Angion Biomedica Corp.
8-K
001-39990
3.2
February 9, 2021
5.1*
Opinion of Cooley LLP.
23.1*
Consent of Moss Adams LLP, independent registered public accounting firm.
23.3*
Consent of Cooley LLP (included in Exhibit 5.1 hereto).
24.1*
Power of Attorney (included on the signature page hereto).
99.1
Angion Biomedica Corp.  2021 Incentive Award Plan.
10-K
001-39990
10.6(a)
March 30, 2022
99.2
Form of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.
10-K
001-39990
10.6(b)
,
10.6(c)
,
10.6(d)
March 30, 2022
99.3
Angion Biomedica Corp. 2021 Employee Stock Purchase Plan.
10-K
001-39990
10.7
March 30, 2022
107*
Filing Fee Table
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
      caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Park City, State of Utah, on this 17th day of March, 2023.
ANGION BIOMEDICA CORP.
By:
/s/
Jay Venkatesan
Jay Venkatesan, M.D.
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jay R. Venkatesan, M.D. and Jennifer J. Rhodes, and each one of them, as his or her true and lawful
      attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration
      Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and
      perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
      or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Jay R. Venkatesan, M.D.
Chief Executive Officer and Director
March 17, 2023
Jay R. Venkatesan, M.D.
(Principal Executive Officer)
/s/ Gregory S. Curhan
Chief Financial Officer and Director
March 17, 2023
Gregory S. Curhan
(Principal Financial and Accounting Officer)
/s/ Itzhak D. Goldberg, M.D.
Director
March 17, 2023
Itzhak D. Goldberg, M.D.
/s/ Victor F. Ganzi
Director
March 17, 2023
Victor F. Ganzi
/s/ Allen R. Nissenson, M.D.
Director
March 17, 2023
Allen R. Nissenson, M.D.
/s/ Gilbert S. Omenn, M.D., Ph.D.
Director
March 17, 2023
Gilbert S. Omenn, M.D., Ph.D.
/s/ Karen J. Wilson
Director
March 17, 2023
Karen J. Wilson